[Ramipril treatment of heart failure in disseminated forms of pulmonary tuberculosis].
A total of 108 patients with heart failure-complicated disseminated pulmonary tuberculosis were followed up. Fifty eight patients received combined therapy including the angiotensin-converting enzyme inhibitor ramipril in a daily dose of 0.25-0.50 mg for 1.5-2 months. Fifty ramipril-untreated patients comprised a control group. Examinations revealed the benefits of the agent in decompensatory chronic cor pulmonale as improved right ventricular systolic and diastolic functions and health in the patients.
A E
AE
Ditiatkov
A E
AE
Radzevich
V A
VA
Tikhonov
I G
IG
Gal'
D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D002908:Chronic Disease; D004452:Echocardiography; D005260:Female; D006333:Heart Failure / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011660:Pulmonary Heart Disease / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D017257:Ramipril / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D014397:Tuberculosis, Pulmonary / Q000150:complications*
D000806:Angiotensin-Converting Enzyme Inhibitors; D017257:Ramipril
Lechenie serdechnoĭ nedostatochnosti pri rasprostranennykh formakh tuberkuleza legkikh s ispol'zovaniem ramiprila.